PXD069096 is an
original dataset announced via ProteomeXchange.
Dataset Summary
| Title | FVIII peptides presented on HLA-DP and identification of an A3 domain peptide binding with high affinity to the commonly expressed HLA-DP4 |
| Description | The development of neutralizing antibodies (inhibitors) against coagulation factor VIII (FVIII) poses a major challenge in hemophilia A (HA) treatment. The formation of FVIII inhibitors is a CD4+ T-cell-dependent mechanism which includes anti- gen presenting cells (APC), B- and T-helper lymphocytes. APC present FVIII-derived peptides on major histocompatibility complex class II (MHC-II) to CD4+ T cells. We previously established a mass spectrometry-based approach to delineate the FVIII repertoire presented on HLA-DR and HLA-DQ. In this study, specific attention was directed towards the identification of FVIII peptides presented on HLA-DP. A data-set of naturally processed FVIII peptides was generated by incubating human FVIII with immature monocyte-derived dendritic cells (moDC) from HLA-typed healthy donors. Using this method, we iden- tified 176 to 1,352 different HLA-DP presented peptides per donor, including 26 different FVIII-derived peptides. The most frequently presented peptides derived from the A3 and C2 domains of FVIII. Comparison of the FVIII repertoire presented on HLA-DP with that presented on HLA-DR revealed considerable overlap but also suggested preferential presentation of specific peptides on either HLA-DR or HLA-DP. Fourteen FVIII peptides presented on HLA-DP were synthesized and evalu- ated for their binding ability to the commonly expressed HLA-DP4 molecule which is highly prevalent in the Caucasian population. Peptide binding studies showed that 7 of 14 peptides competed with a reference peptide to HLA-DP4. Interest- ingly, an A3 domain-derived peptide bound with high affinity to HLA-DP4, positioning this peptide as a prime candidate for the development of novel peptide-based tolerogenic strategies for FVIII inhibitors. |
| HostingRepository | PRIDE |
| AnnounceDate | 2025-10-03 |
| AnnouncementXML | Submission_2025-10-03_01:17:27.373.xml |
| DigitalObjectIdentifier | |
| ReviewLevel | Peer-reviewed dataset |
| DatasetOrigin | Original dataset |
| RepositorySupport | Unsupported dataset by repository |
| PrimarySubmitter | Arie Hoogendijk |
| SpeciesList | scientific name: Homo sapiens (Human); NCBI TaxID: 9606; |
| ModificationList | monohydroxylated residue |
| Instrument | Orbitrap Fusion Lumos |
Dataset History
| Revision | Datetime | Status | ChangeLog Entry |
| 0 | 2025-10-02 14:02:40 | ID requested | |
| ⏵ 1 | 2025-10-03 01:17:28 | announced | |
Publication List
| 10.3324/haematol.2024.286204; |
| Miranda M, Hansen BE, Wehbi B, Porcheddu V, Van Alphen FPJ, Kaijen P, Fijnvandraat K, Lacroix-Desmazes S, Van den Biggelaar M, Maillere B, Voorberg J, Consortium E, FVIII peptides presented on HLA-DP and identification of an A3 domain peptide binding with high affinity to the commonly expressed HLA-DP4. Haematologica, 110(6):1316-1327(2025) [pubmed] |
Keyword List
| submitter keyword: hemophilia A, inhibitors, immunity,factor VIII |
Contact List
| A.J. Hoogendijk |
| contact affiliation | Sanquin Research, Amsterdam, NL |
| contact email | a.hoogendijk@sanquin.nl |
| lab head | |
| Arie Hoogendijk |
| contact affiliation | Sanquin Research, Amsterdam |
| contact email | a.hoogendijk@sanquin.nl |
| dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2025/10/PXD069096 |
| PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD069096
- Label: PRIDE project
- Name: FVIII peptides presented on HLA-DP and identification of an A3 domain peptide binding with high affinity to the commonly expressed HLA-DP4